Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| INCYTE | 2 | 25 | -1,19 % | ||
| BIONTECH | 2 | 13 | -0,51 % | ||
| DAY ONE BIOPHARMACEUTICALS | 1 | 3 | +65,75 % | ||
| CRISPR THERAPEUTICS | 1 | 1 | -1,23 % | ||
| TEMPUS AI | 1 | 1 | -0,44 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | -3,02 % | ||
| ATAIBECKLEY | 1 | - | -3,27 % | ||
| BIOGEN | - | 54 | -1,00 % | ||
| AMGEN | - | 27 | -0,74 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | -0,28 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 1 | Seeking Alpha | ||
| Sa | AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg | 7 | Seeking Alpha | ||
| Sa | Incyte meldet die Zulassung von Zynyz (Retifanlimab) durch die Europäische Kommission für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) | 363 | Business Wire | Zynyz (Retifanlimab) in Kombination mit Carboplatin und Paclitaxel (platinbasierte Chemotherapie) ist die erste systemische Therapie für erwachsene Patienten mit fortgeschrittenem SCAC in Europa ... ► Artikel lesen | |
| Sa | BioNTech-Aktie: Warnsignal - Könnte am Montag komplett einbrechen! | Hebelschein-Spekulant | |||
| Sa | Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant | 5 | Seeking Alpha | ||
| Sa | CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street | 3 | Insider Monkey | ||
| Sa | Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine | 8 | Insider Monkey | ||
| Sa | ANAVEX LIFE SCIENCES CORP: Stabilität als Signal | 1 | Maximilian Berger | ||
| Fr | Oppenheimer bestätigt Immuneering-Rating nach Fortschritten in der Produktpipeline | 4 | Investing.com Deutsch | ||
| Fr | Oppenheimer reiterates Immuneering stock rating on pipeline progress | 1 | Investing.com | ||
| Fr | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | AtaiBeckley Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Fr | AtaiBeckley Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Fr | INCYTE CORP - 8-K, Current Report | 5 | SEC Filings | ||
| Fr | Raymond James reiterates Legend Biotech stock rating after rival approval | 2 | Investing.com | ||
| Fr | Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) | 417 | Business Wire | Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe - The EC approval... ► Artikel lesen | |
| Fr | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 1 | MedCity News | ||
| Fr | Savara receives FDA day 74 letter for autoimmune PAP drug | 2 | Investing.com | ||
| Fr | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| Fr | Jefferies reiterates atai Life Sciences stock rating on pipeline progress | 2 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.